The full name of the drug Anicor is Paianprilizumab, which has the ability to activate the body’s autoimmune system function and can play an indirect role in anti-cancer treatment. Paianprilizumab is a kind of immune checkpoint inhibitor drug (PD1 inhibitor). This drug can activate and restore the body’s own immune system function when it enters the body, which can recognize cancer cells entering the body, and then make the immune effect T cells with killing effect kill the cancer cells, which can indirectly play the effect of anti-cancer treatment. Positive results from clinical studies of pembrolizumab have led to its approval for the treatment of patients with refractory Hodgkin’s lymphoma who have already undergone first- and second-line treatments and whose disease has progressed again. Paianprilizumab needs to be used under the supervision of a specialist such as an oncologist.